2026 National Sunscreen Partner We are proud to share that burnd Sunscreen has joined AIM at Melanoma as our 2026 National Sunscreen Partner. This…
Young Adult Cancer & Mental Health In this episode of Beyond the Clinic: Living Well with Melanoma, host Dr. Samantha Siegel sits down with Dr. Victoria…
Uveal Melanoma Webinar: Part II — Navigating Treatment in the Metastatic Setting Presented in partnership with Save Your Skin Foundation and Ocumel CanadaOcumel Canada (OC), is powered by Save Your Skin Foundation,…
Wade Watson, Stage III Melanoma Survivor A Diagnosis That Changed Everything In early 2021, Wade Watson and his father received life-changing news just weeks apart. His…
Advocates Renew Call for RP1 Approval As the U.S. Food and Drug Administration approaches a pivotal decision on a potential new treatment for advanced melanoma, patient…
Cancer is More Than a Diagnosis: Mind, Meaning, and Healing Cancer is often spoken about in terms of diagnosis, treatment plans, and survival rates. But there is a quieter, more…
Merlin CP-GEP Becomes the First and Only Gene Expression Profile Test Recommended by NCCN® San Diego, CA & Rotterdam, Netherlands- February 19, 2026 — SkylineDx today announced that the National Comprehensive Cancer Network® (NCCN®) has updated its…
FDA Responds to Patient Advocacy on RP1 + Nivolumab As part of our continued advocacy for patients with advanced melanoma, we are sharing the U.S. Food and Drug Administration’s…
Best-in-Class Real-World Data Support Early Amtagvi® Treatment in Advanced Melanoma 52% Amtagvi Response Rate with Two or Fewer Prior Lines of Therapy 73% Overall Disease Control Rate SAN CARLOS, Calif., Feb.…
Moderna, Merck’s Skin Cancer Vaccine Shows Sustained Benefit in Five-Year Follow-Up By Kamal Choudhury and Mariam E SunnyJanuary 20, 2026 3:52 PM EST Jan 20 (Reuters) – Moderna (MRNA.O), opens new tab and Merck…